Pathios Therapeutics
UK - AbingdonBiotechnology
Focus: Pathios Therapeutics is a UK-based biotech focused on novel small-molecule modulators of GPR65 for oncology indications. The company is in Series B stage with a single Phase 1/2 program in clinical development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
0
About Pathios Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Pathios Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PTT-4256
Advanced Solid TumorClinical Trials (1)
NCT06634849An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Phase 1/2Help build intelligence for Pathios Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.